Human wildtype tau expression in cholinergic pedunculopontine tegmental neurons is sufficient to produce PSP‐like behavioural deficits and neuropathology

Progressive Supranuclear Palsy (PSP) is the most common atypical parkinsonism and exhibits hallmark symptomology including motor function impairment and dysexecutive dementia. In contrast to Parkinson's disease, the underlying pathology displays aggregation of the protein tau, which is also see...

Full description

Saved in:
Bibliographic Details
Published inThe European journal of neuroscience Vol. 54; no. 10; pp. 7688 - 7709
Main Authors King, Gabriella, Veros, Kaliana M., MacLaren, Duncan Archibald Allan, Leigh, Martin Peter Konrad, Spernyak, Joseph A., Clark, Stewart D.
Format Journal Article
LanguageEnglish
Published France Wiley Subscription Services, Inc 01.11.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Progressive Supranuclear Palsy (PSP) is the most common atypical parkinsonism and exhibits hallmark symptomology including motor function impairment and dysexecutive dementia. In contrast to Parkinson's disease, the underlying pathology displays aggregation of the protein tau, which is also seen in disorders such as Alzheimer's disease. Currently, there are no pharmacological treatments for PSP, and drug discovery efforts are hindered by the lack of an animal model specific to PSP. Based on previous results and clinical pathology, it was hypothesized that viral deposition of tau in cholinergic neurons within the hindbrain would produce a tauopathy along neural connections to produce PSP‐like symptomology and pathology. By using a combination of ChAT‐CRE rats and CRE‐dependent AAV vectors, wildtype human tau (the PSP‐relevant 1N4R isoform; hTau) was expressed in hindbrain cholinergic neurons. Compared to control subjects (GFP), rats with tau expression displayed deficits in a variety of behavioural paradigms: acoustic startle reflex, marble burying, horizontal ladder and hindlimb motor reflex. Postmortem, the hTau rats had significantly reduced number of cholinergic pedunculopontine tegmentum and dopaminergic substantia nigra neurons, as well as abnormal tau deposits. This preclinical model has multiple points of convergence with the clinical features of PSP, some of which distinguish between PSP and Parkinson's disease. Cre‐dependent AAV constructs expressing either GFP or hTau was injected into the PPT of ChAT‐CRE rats (A‐B). Within weeks, the hTau expressing group showed significant behavioural deficits (C; motor—horizontal ladder) and tau pathology (D; AT8) that are consistent with PSP.
Bibliography:Funding information
Gabriella King and Kaliana M. Veros contributed equally to this work
Roswell Park's Core Grant, Grant/Award Number: P30CA016056; National Institutes of Health, Grant/Award Number: NS117628; CurePSP, Grant/Award Number: 603‐9‐15
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Joseph A. Spernyak – performed the MRI sessions and supervised the MRI analysis, as well as contributed to writing the manuscript
Duncan A.A. MacLaren – performed preliminary experiments, collaborated on study design, and contributed to writing the manuscript
Martin P.K. Leigh – performed MRI analysis and contributed to editing the manuscript
Gabriella King – performed the histological experiments and analysis, as well as contributed to the writing of the manuscript
Kaliana M. Veros – performed the surgeries and behavioral experiments and analysis, as well as contributed to the writing of the manuscript
Author Contributions
Stewart D. Clark – Supervised the study, as well as collaborated on the study design and contributed to the writing of the manuscript.
these authors contributed equally to this work
ISSN:0953-816X
1460-9568
1460-9568
DOI:10.1111/ejn.15496